Shlomit Barzilai-Birenboim, David M Zucker, Galia Avrahami, Sarah Elitzur, Salvador Fisher, Sarah Ganem, Gil Gilead, Shai Izraeli, Gili Kadmon, Eytan Kaplan, Aviva Krauss, Elhanan Nahum, Ron Rabinowicz, Jerry Stein, Osnat Tausky, Avichai Weissbach, Talya Wittmann Dayagi, Joanne Yacobovich, Asaf D Yanir
{"title":"Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis.","authors":"Shlomit Barzilai-Birenboim, David M Zucker, Galia Avrahami, Sarah Elitzur, Salvador Fisher, Sarah Ganem, Gil Gilead, Shai Izraeli, Gili Kadmon, Eytan Kaplan, Aviva Krauss, Elhanan Nahum, Ron Rabinowicz, Jerry Stein, Osnat Tausky, Avichai Weissbach, Talya Wittmann Dayagi, Joanne Yacobovich, Asaf D Yanir","doi":"10.1080/10428194.2025.2521650","DOIUrl":null,"url":null,"abstract":"<p><p>Children with hematological malignancies, are often hospitalized in pediatric intensive care units (PICU) for sepsis with high mortality and re-admission rates. Risk factors for both are inconsistent. We reviewed data of 190 admissions of children with hematological malignancies to PICU for sepsis. Survival rate (SR) was 85%. Mortality risk factors were: non-complete remission (<i>p</i> < 0.01) and status post-stem cell transplantation (<i>p</i> = 0.02), and best predictors were inotropic drugs (<i>p</i> < 0.01), and Pediatric logistic organ dysfunction-2 (<i>p</i> < 0.01) scores. Patients with viremia had the lowest SR (50%, 0.001). One-quarter of the children were re-admitted due to sepsis, and risk factors were: High-risk (HR) hematological malignancy (<i>p</i> < 0.01) and lack of central venous line (CVL) removal (<i>p</i> < 0.01). Sepsis remains a major cause of death in children with hematological malignancies, and re-admissions are common. Our findings support the recommendation of removing CVL during sepsis and highlight those at the highest risk for sepsis to consider individualized anti-infectious prophylaxis.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2521650","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Children with hematological malignancies, are often hospitalized in pediatric intensive care units (PICU) for sepsis with high mortality and re-admission rates. Risk factors for both are inconsistent. We reviewed data of 190 admissions of children with hematological malignancies to PICU for sepsis. Survival rate (SR) was 85%. Mortality risk factors were: non-complete remission (p < 0.01) and status post-stem cell transplantation (p = 0.02), and best predictors were inotropic drugs (p < 0.01), and Pediatric logistic organ dysfunction-2 (p < 0.01) scores. Patients with viremia had the lowest SR (50%, 0.001). One-quarter of the children were re-admitted due to sepsis, and risk factors were: High-risk (HR) hematological malignancy (p < 0.01) and lack of central venous line (CVL) removal (p < 0.01). Sepsis remains a major cause of death in children with hematological malignancies, and re-admissions are common. Our findings support the recommendation of removing CVL during sepsis and highlight those at the highest risk for sepsis to consider individualized anti-infectious prophylaxis.
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor